AR068552A1 - Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas - Google Patents

Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Info

Publication number
AR068552A1
AR068552A1 ARP080104172A ARP080104172A AR068552A1 AR 068552 A1 AR068552 A1 AR 068552A1 AR P080104172 A ARP080104172 A AR P080104172A AR P080104172 A ARP080104172 A AR P080104172A AR 068552 A1 AR068552 A1 AR 068552A1
Authority
AR
Argentina
Prior art keywords
polypeptides
phage
omegamru
cells
microbial cells
Prior art date
Application number
ARP080104172A
Other languages
English (en)
Original Assignee
Pastoral Greenhouse Gas Res Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pastoral Greenhouse Gas Res Lt filed Critical Pastoral Greenhouse Gas Res Lt
Publication of AR068552A1 publication Critical patent/AR068552A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
    • Y02P60/22—Methane [CH4], e.g. from rice paddies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)

Abstract

Composiciones y métodos para la administracion de moléculas inhibidoras en células microbianas, en particular, células metanogenas. Específicamente, se refiere al omegamru fago recientemente identificado, que incluye la induccion del fago, partículas del fago, y el genoma del fago, y también polipéptidos del fago, así como también polinucleotidos que codifican estos polipéptidos. También se refiere a vectores de expresion y células huésped para la produccion de estos polipéptidos, a métodos para detectar, apuntar, e inhibir células microbianas, especialmente células metanogenas, utilizando el fago revelado, polipéptidos, polinucleotidos, vectores de expresion, y células huésped, también posee composiciones farmacéuticas que comprenden el fago omegamru.
ARP080104172A 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas AR068552A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97510407P 2007-09-25 2007-09-25
US98984107P 2007-11-22 2007-11-22
US98984007P 2007-11-22 2007-11-22

Publications (1)

Publication Number Publication Date
AR068552A1 true AR068552A1 (es) 2009-11-18

Family

ID=40511642

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas
ARP080104172A AR068552A1 (es) 2007-09-25 2008-09-25 Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP080104173A AR068553A1 (es) 2007-09-25 2008-09-25 Vacunas y componentes de vacuna para la inhibicion de celulas microbianas
ARP080104171A AR068551A1 (es) 2007-09-25 2008-09-25 Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas

Country Status (17)

Country Link
US (7) US8586709B2 (es)
EP (5) EP2203466B1 (es)
JP (5) JP5552053B2 (es)
CN (4) CN107129524B (es)
AR (3) AR068553A1 (es)
AU (4) AU2008305846A1 (es)
BR (5) BRPI0817299A8 (es)
CA (3) CA2700164C (es)
CL (3) CL2008002859A1 (es)
DK (3) DK3327030T3 (es)
ES (3) ES2587595T3 (es)
MX (3) MX2010003328A (es)
NZ (1) NZ745324A (es)
RU (1) RU2528854C2 (es)
UY (3) UY31361A1 (es)
WO (3) WO2009041831A1 (es)
ZA (1) ZA201001933B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586709B2 (en) * 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
DK2445515T3 (en) * 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
KR101701890B1 (ko) 2009-06-26 2017-02-02 뤼산도 아게 항균제
EP2470660A4 (en) 2009-08-27 2013-03-20 Pastoral Greenhouse Gas Res Ltd COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHOBOBROVIBACTERIUM RUMINANTIUM
EA037276B1 (ru) * 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
TWI678374B (zh) * 2012-09-19 2019-12-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
EP2840140B2 (en) * 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
JP6823593B2 (ja) * 2014-11-06 2021-02-03 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ Ｒｎａ誘導型エンドヌクレアーゼの細胞へのペプチド媒介輸送
CN104789675A (zh) * 2015-04-15 2015-07-22 江苏师范大学 一种检测荷斯坦奶牛瘤胃微生物的方法
WO2016178207A1 (en) * 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3484996B1 (en) * 2016-07-14 2020-09-09 Basf Se Fermentation medium comprising chelating agent
JP7234114B2 (ja) * 2016-12-29 2023-03-07 イルミナ インコーポレイテッド 細胞区画内の生体分子への直交アクセスおよび細胞区画内の生体分子のタグ付けのための分析システム
US12473535B2 (en) 2017-01-05 2025-11-18 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Method for preparing reticulocyte simulating particles and platelet simulating particles, and reference control
US10745439B2 (en) * 2017-03-20 2020-08-18 Regents Of The University Of Minnesota Kinase substrates and methods of use thereof
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
EP3592140A1 (en) * 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
EP3880698A4 (en) 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
CN109627301B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin固体稳定剂开发及应用
CA3171721A1 (en) * 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
US20230072496A1 (en) * 2020-04-10 2023-03-09 Liberty Biosecurity, Llc Polypeptide compositions and uses thereof
CN112143747B (zh) * 2020-09-09 2022-09-13 昆明理工大学 一种噬菌体裂解酶及其基因、基因重组表达载体与应用
HUE067496T2 (hu) 2020-12-08 2024-10-28 Ruminant Biotech Corp Ltd Az állatoknak szánt anyagok bejuttatására szolgáló eszközök és módszerek fejlesztése
CN112961217B (zh) * 2021-03-19 2022-11-08 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113121705B (zh) * 2021-04-19 2023-03-24 成都英普博集生物科技有限公司 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用
EP4554616A1 (en) * 2022-07-11 2025-05-21 Arkea Bio Corp. Compositions and methods for reducing methane emissions in ruminant populations
CN115417927A (zh) * 2022-09-08 2022-12-02 南京松天盛科生物科技有限公司 小鼠腹水致敏物及其应用
EP4612293A1 (en) * 2022-11-03 2025-09-10 Helix Nanotechnologies Inc Ruminal and methanogen vaccines and uses thereof
CN115938486B (zh) * 2022-12-06 2023-11-10 内蒙古农业大学 基于图神经网络的抗菌性乳酸菌株筛选方法
WO2025207521A1 (en) * 2024-03-25 2025-10-02 Silage Labs, Inc. Bacteria expressing lysins for inhibition of methanogenesis
WO2025219570A1 (en) 2024-04-17 2025-10-23 Johannes Kepler Universität Linz Composition for inhibiting protein translocation and methods using the same
WO2025233675A1 (en) * 2024-05-10 2025-11-13 Institut Pasteur Use of talosaminidase to regulate populations of archaeal methanogens in industrial, agricultural and medical settings

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159861A (en) * 1875-02-16 Improvement in brooms
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1221635A (fr) * 1983-05-03 1987-05-12 Andre Speecke Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires
GB8815968D0 (en) * 1988-07-05 1988-08-10 Pfizer Ltd Veterinary devices
JPH05219927A (ja) * 1992-02-14 1993-08-31 Gumma Pref Gov 飼料の混合装置及び混合飼料の製造方法
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
JP3651915B2 (ja) * 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
ZA948204B (en) 1993-10-19 1995-06-12 Commw Scient Ind Res Org Method for improving utilisation of nutrients by ruminant or ruminant-like animals
NZ278977A (en) 1994-01-20 1997-03-24 Pastoral Agric Res Inst Nz Ltd Sustained release bolus for ruminants
EP0739198B1 (en) 1994-01-20 2003-09-17 Agresearch Limited Device for administration of beneficial materials to ruminants
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
AUPN353695A0 (en) 1995-06-14 1995-07-06 Commonwealth Scientific And Industrial Research Organisation Immunogenic preparation and method for improving the productivity of ruminant animals
WO1998007830A2 (en) * 1996-08-22 1998-02-26 The Institute For Genomic Research COMPLETE GENOME SEQUENCE OF THE METHANOGENIC ARCHAEON, $i(METHANOCOCCUS JANNASCHII)
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
AU2002326949A1 (en) 2001-09-18 2003-05-12 The Board Of Regents Of The University Of Nebraska Method for the inhibition of methanogenesis
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20060068386A1 (en) * 2002-03-04 2006-03-30 Alexei Slesarev Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
SE523209C2 (sv) * 2002-05-14 2004-04-06 Akzo Nobel Nv Förfarande för att reducera metanbildningen från matspjälkningsaktiviteter hos djur
EP1861490A4 (en) 2005-03-23 2010-11-17 Univ St Louis USE OF ARCHAEA FOR MODULATING NUTRITIONAL FUNCTIONALITY OF GASTROINTESTINAL BIOZOOSIS
US8586709B2 (en) * 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
CN101434924A (zh) * 2008-12-17 2009-05-20 中南大学 一种分离严格厌氧产甲烷古菌的方法
EP2470660A4 (en) * 2009-08-27 2013-03-20 Pastoral Greenhouse Gas Res Ltd COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHOBOBROVIBACTERIUM RUMINANTIUM
CN101864362B (zh) * 2010-05-19 2012-05-09 江苏加德绿色能源有限公司 一种复合微生物菌剂及其应用
DE102011119230B4 (de) * 2011-11-23 2013-07-11 Audi Ag Kraftwagen-Blinkleuchte und Verfahren zum Betreiben einer Blinkleuchte
JP2016511630A (ja) * 2012-12-21 2016-04-21 ダニスコ・ユーエス・インク 代案の下流メバロン酸経路を使用するイソプレン、イソプレノイド、およびイソプレノイド前駆体の生成

Also Published As

Publication number Publication date
WO2009041832A9 (en) 2009-10-22
JP2017046704A (ja) 2017-03-09
BR122021010737B1 (pt) 2021-09-21
ES2587595T3 (es) 2016-10-25
AU2014210649B2 (en) 2016-09-08
CN101932595B (zh) 2016-02-10
US20140220636A1 (en) 2014-08-07
DK3327030T3 (da) 2021-10-04
RU2010116163A (ru) 2011-11-10
BR122020023381B1 (pt) 2021-09-08
UY31361A1 (es) 2009-04-30
CA2700129A1 (en) 2009-04-02
JP2010539928A (ja) 2010-12-24
EP2203466A2 (en) 2010-07-07
US10995120B2 (en) 2021-05-04
BRPI0817299A2 (pt) 2015-06-16
CA2700162A1 (en) 2009-04-02
RU2528854C2 (ru) 2014-09-20
NZ745324A (en) 2023-02-24
CA2700164C (en) 2018-05-29
JP6067209B2 (ja) 2017-01-25
CA2700164A1 (en) 2009-04-02
US20210332087A1 (en) 2021-10-28
WO2009041832A2 (en) 2009-04-02
WO2009041831A9 (en) 2009-11-05
US20170342112A1 (en) 2017-11-30
WO2009041830A9 (en) 2009-08-27
ZA201001933B (en) 2013-10-30
MX340736B (es) 2016-07-22
BRPI0817312A2 (pt) 2015-03-17
WO2009041831A1 (en) 2009-04-02
BRPI0817312B1 (pt) 2018-05-29
EP2203470A2 (en) 2010-07-07
BR122021010729B1 (pt) 2022-02-15
JP2010539926A (ja) 2010-12-24
EP2203467A4 (en) 2011-04-13
ES2625144T3 (es) 2017-07-18
EP2203466B1 (en) 2016-04-06
EP3327030A1 (en) 2018-05-30
AU2008305846A1 (en) 2009-04-02
DK2203466T3 (en) 2016-07-25
CL2008002861A1 (es) 2009-03-06
CA2700129C (en) 2021-07-20
US8592556B2 (en) 2013-11-26
CN107129524B (zh) 2023-11-21
DK2203467T3 (en) 2017-03-27
CN107129524A (zh) 2017-09-05
CN101918431B (zh) 2014-10-08
UY31359A1 (es) 2009-04-30
AR068551A1 (es) 2009-11-18
AU2008304019A1 (en) 2009-04-02
WO2009041832A3 (en) 2009-06-11
CN101918431A (zh) 2010-12-15
AU2014210649A1 (en) 2014-09-04
US20100221185A1 (en) 2010-09-02
MX2010003328A (es) 2010-08-16
AR068553A1 (es) 2009-11-18
US8586709B2 (en) 2013-11-19
JP5558356B2 (ja) 2014-07-23
CN101932595A (zh) 2010-12-29
EP3327030B1 (en) 2021-07-21
JP2015042166A (ja) 2015-03-05
BRPI0817299A8 (pt) 2019-01-29
US20100209998A1 (en) 2010-08-19
CA2700162C (en) 2018-08-14
AU2008304018A1 (en) 2009-04-02
US9296789B2 (en) 2016-03-29
UY31360A1 (es) 2009-04-30
EP2203470A4 (en) 2011-04-13
WO2009041830A2 (en) 2009-04-02
CL2008002860A1 (es) 2009-06-05
NZ780936A (en) 2024-08-30
JP5552053B2 (ja) 2014-07-16
JP2010539927A (ja) 2010-12-24
EP2203467A1 (en) 2010-07-07
WO2009041830A3 (en) 2009-07-02
US20100209999A1 (en) 2010-08-19
CL2008002859A1 (es) 2009-03-06
CN102015755A (zh) 2011-04-13
MX2010003321A (es) 2010-08-03
US20200325180A1 (en) 2020-10-15
US10590170B2 (en) 2020-03-17
ES2895908T3 (es) 2022-02-23
EP2203467B1 (en) 2016-12-14
EP2203466A4 (en) 2011-04-13
EP3936516A1 (en) 2022-01-12
MX2010003319A (es) 2010-09-10
US11926647B2 (en) 2024-03-12

Similar Documents

Publication Publication Date Title
AR068552A1 (es) Polipeptidos y polinucleotidos del fago omegamru y sus usos para detectar, apuntar e inhibir celulas microbianas metanogenicas
AR077992A1 (es) Secuencia del genoma completo del metanogeno methanobrevibacter ruminantium
EA201290295A1 (ru) Специфичные к рецептору меланокортина-1 линейные пептиды
CR20190319A (es) ANTICUERPOS CONTRA EL INHIBIDOR DEL ACTIVADOR DE PLASMINÓGENO TIPO 1 (PAI-1) Y USOS DE LOS MISMOS (Divisional 2016-0117)
CL2015001353A1 (es) Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
PY1147875A (es) Polipéptidos de enlace de los receptores de quimiocina
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
BR112018001660A2 (pt) células exterminadoras naturais e linhagens de células exterminadoras naturais modificadas possuindo citotoxicidade aumentada
CL2015001790A1 (es) Compuestos derivados de 3,4-dihidroisoquinolina sustituidos, inhibidores de prmt5; composicion farmaceutica; kit farmaceutico; metodo de inhibicion de prmt5; metodo para tratar la expresion de un gen; metodo para alterar la transcripcion; metodo de tratamiento de un trastorno tal como cancer, diabetes y obesisdad, entre otros.
MX2016001044A (es) Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
DOP2013000209A (es) Inhibidores de glucosilceramida sintasa
CL2011000957A1 (es) Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
EP2361988A4 (en) MOLECULAR MARKER FOR CANCER STYLE CELL
IN2015DN03029A (es)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
BR112015021708A2 (pt) Inibidor de polipetídeo do tnfa, polinucleotídeo isolado, estrutura de expressão de ácido nucleico, célula de planta, composição farmacêutica e método de produção de um inibidor de polipeptídeo do tnfa
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX351599B (es) Polimeros cationicos con base en glucogeno.
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
MX2011008885A (es) Composiciones, sintesis y metodos para usar derivados de arilpiperazina.
PH12015500515A1 (en) Beta-glucosidase from magnaporthe grisea

Legal Events

Date Code Title Description
FB Suspension of granting procedure